Shots:
RNAi therapeutics are innovative medications that enable rapid identification of specific inhibitors of disease targets across a wide range of molecule classes. Several biopharma companies are investing in RNAi therapeutics extravagantly to maintain a healthy foothold in innovative medicines
In 2023, the global RNAi drug delivery market size was valued at $84.1B and is…
Shots:
An American investment firm, OrbiMed Advisor is a prominent name when it comes to healthcare investments. The company boasts a robust portfolio of more than 180 companies, including AbCellera, Acelyrin, Actus Medical, and Adaptive Biotechnologies, among others
In 2023, OrbiMed invested in 38 funding rounds; 11, 6, 9 & 12 every quarter across 2023…
Shots:
Sticking to M&A and licensing agreements can be really challenging, especially when dealing with stringent antitrust laws and evolving regulatory challenges. In such adverse scenarios, the rational and right step seems to be nullifying the existing deals.
In 2023, the termination of the deal between Janssen and Arrowhead remained the talk of the town…
Shots:
Driven by innovations and propelled by the pursuit of delivering the best-in-class therapies, 2023 remained a good year for the Biopharma Industry, despite a slight revenue decline, partly due to the conclusion of the COVID-19 pandemic
With a CAGR of 7.8 %, the global biopharma industry is anticipated to register a market size of…
Shots:
Clinical-stage biopharma companies are in constant need of funding and the best way to pull in money in such dire situations is by going public. 2023 had been a great year for Wall Streets across the globe with continuous announcements of IPOs
Kenvue by bagging $4.37B upon completion of its IPO ranked first in…
Shots:
While the World celebrated International Women’s Day, PharmaShots was busy preparing an exciting report on the Top 20 Women Health Focusing Companies Based on Market Cap
Women's Health Market size was valued at $38.10B in 2023 and is expected to register $58.10B by 2030 with a CAGR of 4.9 percent. AbbVie managed to secure…
Shots:
With diverse applications in diagnostic imaging, theragnostics, and targeted therapy, radiopharmaceuticals are gradually tapping into an ocean of unlimited opportunities
By 2030, the radiopharmaceutical market size is expected to grow to $12.18B. In 2023, POINT Biopharma topped the list among radiopharma companies with a market cap of $726.88B followed by Novartis with a market…
Shots:
Driven by mutual growth and expansion, strategic collaborations are embedded deeply in the modus operandi of life sciences deals. In 2023, the volume of life science deals was comparatively high vs. 2022
The collaboration deal between Daiichi Sankyo and Merck & Co. for $22B ranks first in our list followed by the development and…
Shots:
With stringent antitrust regulation clasping the overall volume of M&A deals, the biopharma industry manages to hold up a few strong M&A while conquering the waves of unexpected economic turmoil in 2023
In 2023, the global biopharma industry witnessed an astounding transformation with M&A deals. Pfizer’s acquisition of Seagen for $43B ranks first in…
Shots:
The animal health industry is involved in a wide variety of services, from disease prevention to addressing insatiable nutritional needs. This sector not only protects us from potential zoonotic diseases but also delivers food of high quality derived from animals
In 2022, the animal health industry was valued at $58.66B. By 2030, the global animal health…

